Postmenopausal Osteoporosis Market, by Drug Class (Bisphosphonates, Selective Estrogen Receptor Modulators (SERMs), RANK Ligand Inhibitors, Anabolic Class, Calcium Metabolism Modifiers, and Others (Calcitonin, Denosumab among Others)), by Route of Adminis

Postmenopausal Osteoporosis Market, by Drug Class (Bisphosphonates, Selective Estrogen Receptor Modulators (SERMs), RANK Ligand Inhibitors, Anabolic Class, Calcium Metabolism Modifiers, and Others (Calcitonin, Denosumab among Others)), by Route of Administration (Oral, Intravenous Route, and Subcutaneous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Osteoporosis is a medical condition in which the bones become brittle and fragile due to decreased bone mass and bone mineral density, leading to frequent fragility fractures. Worldwide, one in three women over the age of 50 is at risk of developing osteoporosis. It could be due to hormonal changes or a lack of calcium and vitamin D. Along with increased incidences of fractures in older, postmenopausal women, osteoporosis may often lead to mobility loss and perhaps morbidity and death. A major reason for developing this disease and the associated bone loss in women is estrogen deficiency. Other important risk factors are genetics, advanced age, being underweight, smoking, alcohol abuse, etc. Ample intake of protein, calcium, and vitamin D may help prevent postmenopausal osteoporosis without pharmacologic means. Doctors also suggest regular physical activity and avoiding smoking and alcohol consumption to lower the risk. For premenopausal women (women naturally approaching menopause) and those with low bone density and other risk factors, estrogen and drugs are recommended for improved bone density and strength.

Market Dynamics

Increasing inorganic growth activities such as agreements among market players is expected to drive the growth of the global postmenopausal osteoporosis market over the forecast period. For instance, on June 10, 2021, Theramex UK Ltd, a global specialty pharmaceutical company announced a license and supply agreement with Enzene Biosciences Limited, a Biotechnology company for the registration and commercialization of Denosumab, an antiresorptive treatment for osteoporosis.

Key features of the study:

• This report provides an in-depth analysis of the global postmenopausal osteoporosis market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global postmenopausal osteoporosis market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Pfizer Inc., F. Hoffmann-La Roche Ltd, Mylan N.V. (Viatris Inc.), Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd, Ligand Pharmaceuticals Incorporated, Paras Biopharmaceuticals Finland Oy, Eli Lilly and Company, TRANSCENTA HOLDING, Amgen, Gedeon Richter Plc., Enzene Biosciences, Samsung BioepisL Radius Health, Inc., Alvotech, and AryoGen Pharmed
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global postmenopausal osteoporosis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global postmenopausal osteoporosis market

Detailed Segmentation:

• Global Postmenopausal Osteoporosis Market, By Drug Class:
• Bisphosphonates
• Selective Estrogen Receptor Modulators (SERMs)
• RANK Ligand Inhibitors
• Anabolic Class
• Calcium Metabolism Modifiers
• Others (Calcitonin, Denosumab, among Others)
• Global Postmenopausal Osteoporosis Market, By Route of Administration:
• Oral
• Intravenous Route
• Subcutaneous
• Global Postmenopausal Osteoporosis Market By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Postmenopausal Osteoporosis Market, By Region:
• North America
• By Country:
• U.S.
• Canada
• Latin America
• By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country:
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country:
• GCC
• Israel
• Rest of Middle East
• Africa
• By Country/Region:
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Pfizer Inc.*
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• F.Hoffmann-La Roche Ltd
• Mylan N.V. (Viatris Inc.)
• Fresenius Kabi AG
• Hikma Pharmaceuticals PLC
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• GlaxoSmithKline plc
• Sun Pharmaceutical Industries Ltd
• Ligand Pharmaceuticals Incorporated
• Paras Biopharmaceuticals Finland Oy
• Eli Lilly and Company
• TRANSCENTA HOLDING
• Amgen
• Gedeon Richter Plc.
• Enzene Biosciences
• Samsung BioepisL Radius Health, Inc.
• Alvotech
• AryoGen Pharmed

“*” marked represents similar segmentation in other categories in the respective section.